Sana Biotechnology, Inc. (SANA): Price and Financial Metrics
SANA Price/Volume Stats
| Current price | $8.26 | 52-week high | $12.00 |
| Prev. close | $8.41 | 52-week low | $2.74 |
| Day low | $8.15 | Volume | 1,364,400 |
| Day high | $8.59 | Avg. volume | 3,114,826 |
| 50-day MA | $8.79 | Dividend yield | N/A |
| 200-day MA | $5.72 | Market Cap | 1.82B |
SANA Stock Price Chart Interactive Chart >
Sana Biotechnology, Inc. (SANA) Company Bio
Sana Biotechnology, Inc. operates as a biotechnology company. The Company focuses on creating and delivering engineered cells as medicine for patients. Sana Biotechnology replaces damaged cells and tissues and treats broad array of diseases.
Latest SANA News From Around the Web
Below are the latest news stories about SANA BIOTECHNOLOGY INC that investors may wish to consider to help them evaluate SANA as an investment opportunity.
EVP Christian Hordo Sells 75,000 Shares of Sana Biotechnology Inc (SANA)In a notable insider transaction, EVP and Chief Business Officer Christian Hordo sold 75,000 shares of Sana Biotechnology Inc (NASDAQ:SANA) on December 15, 2023. |
Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual MeetingPreclinical data with SC262, a HIP-modified CD22-directed allogeneic CAR T cell, further support completed IND submission Validation of novel and fully-human GPRC5D-specific CARs for the development of a HIP-modified allogeneic GPRC5D-directed CAR T cell therapy SEATTLE, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced preclinical data supporting the anti-tumor and immune e |
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune SystemSEATTLE, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy. SC291 appeared safe and well tolerated, evaded immune detection, a |
Sana Biotechnology to Present at November and December 2023 Investor ConferencesSEATTLE, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in November and December. The presentations will feature a business overview and update. Sana will present at the 6th Annual Evercore ISI HealthCONx Conference at 1:20 p.m. ET on Wednesday, November 29, 2023.Sana will present at the JMP Securities Hem |
Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of GeneticsFlagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo |
SANA Price Returns
| 1-mo | -4.51% |
| 3-mo | 63.24% |
| 6-mo | 169.93% |
| 1-year | 47.76% |
| 3-year | -65.44% |
| 5-year | N/A |
| YTD | 102.45% |
| 2023 | 3.29% |
| 2022 | -74.48% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...